San Francisco startup Structure Therapeutics can be focusing on an oral, at the time-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June each time a mid-phase study showed normal weight loss of about six% and it plans to get started on One more mid-stage demo toward the end of this year—that founder